The Analysis of Antipsychotic Drugs in Human Biosamples by LC-MS - LC-MS in Drug Bioanalysis - page 192

7. Stubner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundorfer G, Moller HJ, Hippius
H, Ruther E (2004) Severe and uncommon involuntary movement disorders due to psychotro-
pic drugs. Pharmacopsychiatry 37(Suppl 1):S54-S64. doi: 10.1055/s-2004-815511
8. Carbone JR (2000) The neuroleptic malignant and serotonin syndromes. Emerg Med Clin
North Am 18(2):317-325
9. Welch R, Chue P (2000) Antipsychotic agents and qt changes. J Psychiatry Neurosci
25(2):154-160
10. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT (2001) Antipsychotics
and the risk of sudden cardiac death. Arch Gen Psychiatry 58(12):1161-1167.
doi: yoa20305 [pii]
11. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom
MC, Stricker BH (2004) Antipsychotics and the risk of sudden cardiac death. Arch Intern Med
164(12):1293-1297. doi : 10.1001/archinte.164.12.1293 , 164/12/1293 [pii]
12. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-
serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99(Suppl):S18-S27
13. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-ht2
and d2 receptor occupancy of olanzapine in schizophrenia: a pet investigation. Am J Psychiatry
155(7):921-928
14. Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van
Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-ht2/1c antagonist, and negative
symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry
163:451-455
15. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47(1):27-38
16. Seeman P, Tallerico T (1999) Rapid release of antipsychotic drugs from dopamine d2 recep-
tors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of
clozapine or quetiapine. Am J Psychiatry 156(6):876-884
17. Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009) Atypical antipsychotic drugs and
the risk of sudden cardiac death. N Engl J Med 360(3):225-235. doi: 360/3/225 [pii] 10.1056/
NEJMoa0806994
18. Muench J, Hamer AM (2010) Adverse effects of antipsychotic medications. Am Fam Physician
81(5):617-622
19. Ananth J, Parameswaran S, Gunatilake S (2004) Antipsychotic polypharmacy. Curr Pharm
Des 10(18):2231-2238
20. Barbui C, Ciuna A, Nose M, Patten SB, Stegagno M, Burti L, Amaddeo F, Tansella M (2004)
Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient prac-
tice. Acta Psychiatr Scand 109(4):275-278. doi: 283 [pii]
21. Fleischhacker WW (2003) Second-generation antipsychotics: Discrepancies between licensed
indications, evidence base and actual use. Psychopharmacology (Berl) 169(2):207-210.
doi: 10.1007/s00213-003-1496-9
22. Barnes TR, Curson DA (1994) Long-term depot antipsychotics. A risk-bene fi t assessment.
Drug Saf 10(6):464-479
23. Milton GV, Jann MW (1995) Emergency treatment of psychotic symptoms. Pharmacokinetic
considerations for antipsychotic drugs. Clin Pharmacokinet 28(6):494-504
24. Jones B, Taylor CC, Meehan K (2001) The efficacy of a rapid-acting intramuscular formula-
tion of olanzapine for positive symptoms. J Clin Psychiatry 62(Suppl 2):22-24
25. Jorgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin L, Malm U (1982) Serum concen-
trations of cis(z)-flupentixol and prolactin in chronic schizophrenic patients treated with
flupentixol and cis(z)-flupentixol decanoate. Psychopharmacology (Berl) 77(1):58-65
26. Maurer HH (1992) Systematic toxicological analysis of drugs and their metabolites by gas
chromatography-mass spectrometry. J Chromatogr 580(1-2):3-41
27. Arinobu T, Hattori H, Iwai M, Ishii A, Kumazawa T, Suzuki O, Seno H (2002) Liquid chro-
matographic-mass spectrometric determination of haloperidol and its metabolites in human
plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 776(1):107-113.
doi: S1570023202001757 [pii]